XM does not provide services to residents of the United States of America.
P
P

Pfizer


News

FDA authorizes Novavax's updated COVID vaccine targeting JN.1 strain

UPDATE 4-FDA authorizes Novavax's updated COVID vaccine targeting JN.1 strain Updates shares, adds company comment in paragraph 6 By Sriparna Roy Aug 30 (Reuters) - The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's NVAX.O COVID shot. The updated vaccine is authorized for use in individuals 12 years of age and older and will target the JN.1 strain of the virus.
P

What to Watch in the Weak Ahead and on Tuesday, September 3

What to Watch in the Weak Ahead and on Tuesday, September 3 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON TUESDAY On the U.S. economic calendar, S&P Global's final reading of manufacturing Purchasing Managers' Index (PMI) for August is slated for release.
G
P
D

Alnylam shares slide after heart drug data fails to impress investors

Alnylam shares slide after heart drug data fails to impress investors Aug 30 (Reuters) - Alnylam Pharmaceuticals' ALNY.O shares fell nearly 11% before the bell on Friday, after data for its closely watched heart drug fell short of heightened investor expectations. The company's shares have climbed more than 70% since it disclosed early results of the late-stage study of the drug, vutrisiran , in June.
P

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

UPDATE 3-Delaware top court will hear drugmakers' appeal to end Zantac lawsuits Adds response from plaintiffs' attorneys in paragraph 5 By Brendan Pierson Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer.
G
P
S

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. GSK, Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim are asking the court to overturn an order by a lower court judge allowing plaintiffs in the lawsuits to offer expert testimony on the alleged cancer lin
G
P
S

Hims & Hers Health falls after Lilly launches single-dose vials of weight-loss drug

BUZZ-Hims & Hers Health falls after Lilly launches single-dose vials of weight-loss drug ** Shares of telehealth company Hims & Hers Health HIMS.N fall 5% to $15.25 premarket ** Eli Lilly LLY.N says it has begun selling single-dose vials of its popular weight-loss drug Zepbound in the U.S. through its LillyDirect website ** The 2.5 milligram and 5
P

Pfizer Launches Pfizerforall™, A Digital Platform That Helps Simplify Access To Healthcare

BRIEF-Pfizer Launches Pfizerforall™, A Digital Platform That Helps Simplify Access To Healthcare Aug 27 (Reuters) - Pfizer Inc PFE.N : PFIZER LAUNCHES PFIZERFORALL™, A DIGITAL PLATFORM THAT HELPS SIMPLIFY ACCESS TO HEALTHCARE PFIZER INC - PFIZERFORALL DESIGNED FOR MIGRAINE, COVID-19, FLU PATIENTS PFIZER INC - PFIZERFORALL OFFERS HOME DELIVERY OF MEDICINES PFIZER: WORKING WITHIN EXISTING U.S.
P

Pfizer launches new website for migraine, respiratory offerings

Pfizer launches new website for migraine, respiratory offerings By Michael Erman Aug 27 (Reuters) - Pfizer Inc PFE.N is launching a new website to promote and improve access to its health care offerings for migraine and respiratory illnesses. The drugmaker said on Tuesday that it launched the site called PfizerForAll to help patients get access to treatments like its COVID-19 drug Paxlovid and its migraine pill Nurtec by offering services like telehealth appointments and diagnostic tests.
P

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year By Patrick Wingrove Aug 26 (Reuters) - Cigna CI.N said on Monday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.
A
C
P
T

US CDC To Reopen Free At Home, Covid 19 Test Delivery Programs In Late September

BRIEF-US CDC To Reopen Free At Home, Covid 19 Test Delivery Programs In Late September Aug 23 (Reuters) - US CDC SAYS FREE AT HOME, COVID 19 TEST DELIVERY PROGRAMS WILL REOPEN IN LATE SEPTEMBER -PRESS CONFERENCE US HHS SAYS HAS LAUNCHED NEW NATIONAL CAMPAIGN TO EDUCATE AUDIENCES AT HIGH RISKS OF FLU, COVID, 19 AND RSV -PRESS CONFERENCE US CDC SAYS
P

US to offer free COVID tests in September as part of fall campaign

UPDATE 2-US to offer free COVID tests in September as part of fall campaign Adds details on testing program in paragraph 2, background on COVID infections in paragraph 5, details from press briefing throughout By Manas Mishra and Julie Steenhuysen Aug 23 (Reuters) - The U.S. government will provide free COVID-19 tests by mail starting in late September, as it kicks off a fall campaign urging eligible Americans to get vaccinated against COVID, flu and RSV, health officials said on Friday.
P

Ozempic on Wall Street's list for 2027 Medicare drug negotiations

ANALYSIS-Ozempic on Wall Street's list for 2027 Medicare drug negotiations Novo Nordisk, Pfizer, GSK drugs likely to be in 2027 Medicare negotiations Most drugs already discounted, limited impact seen on Big Pharma Analysts expect price cuts to have bigger bite starting in 2028 By Michael Erman NEW YORK, Aug 23 (Reuters) - Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026 , Wall Street analysts are betting on a 2027 list that will include Novo N
G
P
T

Pfizer- Shipping For Pfizer & Biontech 2024-2025 Covid-19 Vaccine To Begin Shipping Immediately

BRIEF-Pfizer- Shipping For Pfizer & Biontech 2024-2025 Covid-19 Vaccine To Begin Shipping Immediately Aug 22 (Reuters) - Pfizer: PFIZER- SHIPPING FOR PFIZER & BIONTECH 2024-2025 COVID-19 VACCINE TO BEGIN SHIPPING IMMEDIATELY PFIZER- PFIZER & BIONTECH 2024-2025 COVID-19 VACCINE TO BE AVAILABLE ACROSS U.S. BEGINNING IN COMING DAYS
P

US FDA approves updated COVID shots ahead of fall and winter

UPDATE 4-US FDA approves updated COVID shots ahead of fall and winter Adds Novavax response in paragraph 11 By Mariam Sunny and Manas Mishra Aug 22 (Reuters) - The U.S. Food and Drug Administration on Thursday approved updated COVID-19 vaccines made by Pfizer PFE.N and Moderna MRNA.O targeting a recent variant of the disease, in time for a fall vaccination campaign.
P

FDA Approves And Authorizes Updated mRNA Covid-19 Vaccines To Better Protect Against Currently Circulating Variants

BRIEF-FDA Approves And Authorizes Updated mRNA Covid-19 Vaccines To Better Protect Against Currently Circulating Variants Aug 22 (Reuters) - U.S. FDA: FDA APPROVES AND AUTHORIZES UPDATED MRNA COVID-19 VACCINES TO BETTER PROTECT AGAINST CURRENTLY CIRCULATING VARIANTS US FDA: UPDATED MRNA COVID-19 VACCINES INCLUDE COMIRNATY AND SPIKEVAX, BOTH OF WHIC
P

US FDA approves updated COVID shots ahead of fall season

US FDA approves updated COVID shots ahead of fall season Aug 22 (Reuters) - The U.S. Food and Drug Administration has approved updated COVID-19 vaccines made by Pfizer PFE.N and Moderna MRNA.O targeting newer variants of the disease in time for a fall vaccination campaign, the agency said on Thursday. The regulator has approved the vaccines to target a variant known as "KP.2", which dominated infections in recent months, for individuals aged 12 years and above.
P

FDA Says Infants At Risk For Aluminum Toxicity With Unapproved Potassium Phosphates Drug Product

BRIEF-FDA Says Infants At Risk For Aluminum Toxicity With Unapproved Potassium Phosphates Drug Product Aug 21 (Reuters) - FDA: FDA: INFANTS AT RISK FOR ALUMINUM TOXICITY WITH UNAPPROVED POTASSIUM PHOSPHATES DRUG PRODUCT FDA: AWARE THAT SOME HOSPITALS CONTINUE TO BUY HOSPIRA’S UNAPPROVED POTASSIUM PHOSPHATES PRODUCT TO USE IN CHILDREN FDA: ON AUG
P

U.S. STOCKS B Riley, Energy stocks, Pharma stocks

BUZZ-U.S. STOCKS ON THE MOVE-B Riley, Energy stocks, Pharma stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 paused on Friday as investors digested a spate of encouraging economic data that dispelled slowdown concerns and put Wall Street's main indexes on course for their best weekly performance this year.
C
M
P
T
T
U
U
U

U.S. STOCKS Pharma stocks, H & R Block, B Riley Financial

REFILE-BUZZ-U.S. STOCKS ON THE MOVE-Pharma stocks, H & R Block, B Riley Financial Adds dropped names in headline Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes slipped on Friday following the S&P 500 and the Nasdaq's six-day winning streaks after a spate of encouraging economic data allayed recession worries, while weak housing data dampened sentiment.
C
P
T
U
U
U

Pfizer falls as flu-COVID combination shot misses one of the main goals in study

BUZZ-Pfizer falls as flu-COVID combination shot misses one of the main goals in study ** Shares of drugmaker Pfizer PFE.N fall 2.8% to $27.92 ** PFE and BioNTech 22UAy.DE say their experimental combination mRNA vaccine to protect against influenza and COVID-19 failed to meet one of the two main goals in a late-stage study ** Companies say they are
P



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.